# A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone

Study · id `cardio:ct-nct01456169` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01456169](<https://clinicaltrials.gov/study/NCT01456169>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01456169

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 507 participants.

## Technical summary

Registry record NCT01456169. Randomized; quadruple masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2012-12 (actual). Results posted on 2014-04-23.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 507 participants (enrolled count; ClinicalTrials.gov record NCT01456169, source copy `cardio:ctgov-nct01456169-2014-04-23`, retrieved 2026-10-26)
- Start date: 2011-10 (registry gives no type) (ClinicalTrials.gov record NCT01456169, source copy `cardio:ctgov-nct01456169-2014-04-23`, retrieved 2026-10-26)
- Primary completion: 2012-12 (actual) (ClinicalTrials.gov record NCT01456169, source copy `cardio:ctgov-nct01456169-2014-04-23`, retrieved 2026-10-26)
- Completion: 2013-01 (actual) (ClinicalTrials.gov record NCT01456169, source copy `cardio:ctgov-nct01456169-2014-04-23`, retrieved 2026-10-26)
- Results first posted: 2014-04-23 (ClinicalTrials.gov record NCT01456169, source copy `cardio:ctgov-nct01456169-2014-04-23`, retrieved 2026-10-26)
- Countries: Bulgaria; Estonia; France; Germany; Hungary; Italy; Lithuania; Netherlands; Poland; Serbia; Slovakia; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT01456169, source copy `cardio:ctgov-nct01456169-2014-04-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01456169-2014-04-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone
- Condition: Essential Hypertension
- Intervention (Drug): Azilsartan medoxomil/placebo
- Intervention (Drug): Azilsartan medoxomil - chlorthalidone
- Lead sponsor: Takeda
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Takeda (`cardio:org-takeda`)

## Provenance

Content hash: dcfd894e530ebeb9608c8f7cbb37d10954292f4ff71bdbbca3fc501490736ff1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
